FOCUSED ON DEVELOPING AN INNOVATIVE TREATMENT FOR COGNITIVE IMPAIRMENT due to raised cortisol ASSOCIATED WITH NEUROLOGICAL DISEASES

Ethics Committee approval for XanaMIA Study
Actinogen has received approval from the Bellberry Human Research Ethics Committee (HREC) to commence the first part of the XanaMIA study, designed to study improvements in cognitive ability in older volunteers, and patients with Mild Cognitive Impairment (MCI), the first clinical stage of Alzheimer’s Disease.
View ASX Announcement
Change of Share Register Notification
Actinogen Medical changed its provider for shareholder registry services from Link Market Services Limited to Automic Pty Ltd on Monday 31 May 2021. We encourage shareholders that are not already a user of Automic’s investor portal to sign up and register their details via the website https://investor.automic.com.au
View ASX Announcement
Quarterly Activity Report & Appendix 4C
Actinogen Medical released quarterly activity report and Appendix 4C for the three-month period ended 31 March 2021
View ASX Announcement
Previous
Next

About Us

Actinogen Medical  (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

Actinogen Medical’s lead drug candidate, Xanamem®has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. 

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers treated with 20mg Xanamem daily, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company plans to initiate a range of Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.